Compared to Estimates, ANI (ANIP) Q1 Earnings: A Look at Key Metrics

Core Insights - ANI Pharmaceuticals reported $197.12 million in revenue for Q1 2025, a year-over-year increase of 43.4% and an EPS of $1.70 compared to $1.21 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of $179.45 million by 9.85%, and the EPS surpassed the consensus estimate of $1.37 by 24.09% [1] Financial Performance - Net Revenues from Rare Disease and Brands - ILUVIEN and YUTIQ were $16.11 million, below the estimated $19.93 million [4] - Total Net Revenues from Rare Disease were $68.96 million, compared to the estimated $73.36 million [4] - Net Revenues from Rare Disease and Brands - Cortrophin Gel were $52.85 million, slightly below the estimated $53.43 million [4] - Net Revenues from Generic pharmaceutical products were $98.68 million, exceeding the estimated $84.28 million [4] - Total Net Revenues from Generics and Other were $103.04 million, below the estimated $105.45 million, representing a year-over-year change of 2.5% [4] - Net Revenues from Royalties and other pharmaceutical services were $4.36 million, significantly below the estimated $18.32 million [4] Market Performance - ANI's shares returned +9.8% over the past month, while the Zacks S&P 500 composite increased by +13.7% [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential outperformance against the broader market in the near term [3]